Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

MLA

Fabienne Gräbnitz, et al. “Synergistic Cancer Immunotherapy Combines MVA-CD40L Induced Innate and Adaptive Immunity with Tumor Targeting Antibodies.” Nature Communications, vol. 10, Nov. 2019. EBSCOhost, https://doi.org/10.1038/s41467-019-12998-6.

APA

Fabienne Gräbnitz, Ronny Kassub, Barbara Bathke, Sonia T. Wennier, Paul Chaplin, Jose Medina-Echeverz, Marco Testori, Raphael Giessel, Marlene Geiger, Hubertus Hochrein, Henning Lauterbach, Mark Suter, Maria Hinterberger, & Giovanna Fiore. (2019). Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies. Nature Communications, 10. https://doi.org/10.1038/s41467-019-12998-6

Chicago

Fabienne Gräbnitz, Ronny Kassub, Barbara Bathke, Sonia T. Wennier, Paul Chaplin, Jose Medina-Echeverz, Marco Testori, et al. 2019. “Synergistic Cancer Immunotherapy Combines MVA-CD40L Induced Innate and Adaptive Immunity with Tumor Targeting Antibodies.” Nature Communications 10 (November). doi:10.1038/s41467-019-12998-6.